What Innova Therapeutics does

Innova Therapeutics is a privately held, clinical-stage biotechnology company headquartered in Mt. Pleasant, South Carolina (Charleston metro area), developing a monoclonal antibody (mAb) platform and companion diagnostic targeting Secreted Frizzled-Related Protein 2 (SFRP2) for the treatment of solid and hematological cancers. The company's lead asset, IVT-8086, is a humanized monoclonal antibody that selectively blocks the non-canonical Wnt/Calcium (Ca2+) signaling cascade via SFRP2 neutralization, producing multi-faceted anti-cancer activity: tumor reduction, immune restoration (rescuing T-cell dysfunction and reversing exhaustion), angiogenesis inhibition, and tumor-microenvironment modulation (reprogramming tumor-associated macrophages toward an M1 anti-tumor phenotype). A complementary SFRP2 companion diagnostic is in development for early detection, prognostic tracking, and recurrence monitoring. The pipeline spans Discovery, Preclinical, IND, and Phase 1/2A stages, with initial indications focused on pediatric osteosarcoma, sarcomas, pancreatic ductal adenocarcinoma (PDAC), triple-negative breast cancer (TNBC), and multiple myeloma.

The company holds FDA Orphan Drug Designation and Rare Pediatric Disease Designation for IVT-8086 in osteosarcoma, the latter qualifying it for a Priority Review Voucher (PRV) upon approval — historically valued between $80M and $350M on the secondary market as a non-dilutive funding mechanism. Innova has research collaborations with MUSC Hollings Cancer Center and a peer-reviewed publication record across journals including Breast Cancer Research, PLoS ONE, Cancers, Molecular Cancer Therapeutics, Cancer Research, and Annals of Surgical Oncology. In November 2025, the company completed the acquisition of Enci Therapeutics to add IVT-8086 to its pipeline, and CEO Dr. Robert Ryan was recognized with the Global 100 – 2026 Healthcare CEO of the Year award. Leadership includes Robert Ryan as President and CEO and Ronald Nardi as Executive Vice President.

As a pre-commercial biotech with 1–10 employees and no marketed products, Innova Therapeutics does not yet generate product revenue. Its revenue model anticipates future therapeutic product sales of IVT-8086 across multiple oncology indications (both as monotherapy and in combination with standard-of-care chemotherapies and immune checkpoint inhibitors such as PD-1 mAbs), supplemented by licensing/royalty structures and potential PRV monetization. Go-to-market will rely on standard oncology pharmaceutical distribution channels upon regulatory approval, with potential partnership with larger pharmaceutical companies or direct contracting with healthcare systems. The company's go-to-market motion is sales-led, targeting aggressive, high-risk malignancies where unmet medical need is highest.

Name

Innova Therapeutics

Legal name

Innova Therapeutics

Website

https://innovatherapeutics.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Innova Therapeutics is a private, clinical-stage biotech developing IVT-8086, a monoclonal antibody targeting SFRP2 to treat solid and hematological cancers including osteosarcoma, PDAC, and TNBC. It also builds an SFRP2 companion diagnostic for cancer detection and monitoring.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling) (HLAAAMAK)

akta.pro secondary industries

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK)

Keywords

• Monoclonal antibody therapeutics
• Oncology drug development
• Cancer companion diagnostics
• Biopharmaceutical pipeline
• Targeted cancer therapy

Headquarters

HQ city

Isle Of Palms

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. IVT-8086 Monoclonal Antibody (Oncology): As a clinical-stage biotech company, Innova Therapeutics' primary value creation is through the development and potential commercialization of IVT-8086 across multiple oncology indications. Revenue will be derived from therapeutic product sales upon regulatory approval. The company is building a versatile asset with multiple pathways to commercial and clinical success through monotherapy and combination therapy approaches. Priority Review Vouchers (PRVs) from pediatric designations represent a secondary monetization pathway, with recent market valuations ranging between $80M and $350M, providing non-dilutive funding.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Innova Therapeutics is developing IVT-8086, a humanized monoclonal antibody that selectively neutralizes Secreted Frizzled-Related Protein 2 (SFRP2) to block the non-canonical Wnt/Calcium signaling pathway in tumor cells. The therapeutic is intended for aggressive solid and hematologic cancers, initially including pediatric osteosarcoma, sarcomas, pancreatic ductal adenocarcinoma, triple-negative breast cancer, and multiple myeloma. The company also offers a companion diagnostic platform leveraging SFRP2 as a biomarker for early cancer detection, prognostic monitoring, and recurrence tracking.

Product overview

Innova Therapeutics is developing a novel monoclonal antibody (mAb) platform and companion diagnostic targeting Secreted frizzled-related protein-2 (SFRP2). The core platform technology consists of IVT-8086, the company's lead humanized monoclonal antibody candidate designed to treat multiple solid and hematological cancers by blocking the non-canonical Wnt/Calcium signaling pathway. This is complemented by a companion diagnostic platform that utilizes SFRP2 expression for early cancer detection, prognostic tracking, and recurrence monitoring. The company initially focuses on aggressive, high-risk malignancies including pediatric osteosarcoma, sarcomas, pancreatic cancer (PDAC), breast cancer (including triple-negative breast cancer), and multiple myeloma.

Differentiator

Problem solved

Functional benefit

Products and services

• IVT-8086 Lead humanized monoclonal antibody therapeutic candidate that selectively blocks the non-canonical Wnt/Calcium (Ca2+) signaling pathway by neutralizing SFRP2. Designed to treat aggressive solid and hematologic malignancies including pediatric osteosarcoma, sarcomas, pancreatic ductal adenocarcinoma, triple-negative breast cancer, and multiple myeloma. Targeted at pharmaceutical partners, healthcare systems, and (eventually) oncologists treating patients with these cancers.
• SFRP2 Companion Diagnostic Platform Companion diagnostic tool utilizing SFRP2 expression as a biomarker for early cancer detection, prognostic tracking, and recurrence monitoring across solid tumors. Aimed at clinicians, diagnostic laboratories, and oncology centers supporting treatment decisions alongside IVT-8086 therapy.

Quantifiable outcome

• Zero adverse safety effects in monotherapy across multiple animal models including human xenografts and GEMM models
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Enci TherapeuticscoreStrategic or Co-development Partner · 27 November 2025Innova Therapeutics completed the acquisition of Enci Therapeutics, adding its lead oncology program IVT-8086, a monoclonal antibody targeting SFRP2, to its pipeline. IVT-8086 is expected to potentially treat various solid and hematologic cancers by inhibiting pathways involved in tumor growth, angiogenesis, and metastasis. The acquisition significantly expanded Innova's pipeline and added a late preclinical/IND-stage asset.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Emerging players

• Surrozen: Clinical-stage biotech developing antibody-based therapeutics that selectively modulate the Wnt signaling pathway. Comparable as a company targeting Wnt-pathway biology (though focused on regenerative medicine rather than oncology), making it thematically related.
• OncoResponse: Clinical-stage biotech discovering and developing monoclonal antibodies derived from the immune systems of cancer exceptional responders. Comparable as an immuno-oncology mAb developer using novel antibody discovery approaches to target tumor and immune biology.
• Eureka Therapeutics: Clinical-stage biotech developing monoclonal antibodies and T-cell receptor-based therapies for solid tumors, with programs in hepatocellular carcinoma and other aggressive cancers. Comparable as an antibody-platform oncology biotech pursuing hard-to-treat solid tumor indications.
• Werewolf Therapeutics: Clinical-stage biotech developing INDUKINE and PREDATOR platform-based antibody therapeutics that are selectively activated in the tumor microenvironment. Comparable as an emerging antibody-platform oncology company pursuing TME-targeted strategies.
• Inhibrx (acquired by Sanofi): Clinical-stage biotech that developed novel antibody-based therapeutics for oncology and rare diseases. Comparable as an antibody-platform company of similar size and stage before its acquisition by Sanofi, illustrating the strategic exit path for asset-focused mAb biotechs.

Direct peers

• Compass Therapeutics: Clinical-stage biotech with a monoclonal antibody platform focused on immuno-oncology, including antibodies modulating the tumor microenvironment and T-cell function. Directly comparable as a similarly-sized mAb developer pursuing combination strategies with checkpoint inhibitors.
• MacroGenics: Clinical-stage biotech developing monoclonal antibody-based immunotherapies for cancer, including immune checkpoint and bispecific programs. Comparable as a similarly-sized mAb-platform oncology biotech advancing through clinical development with multi-indication strategies.
• Pyxis Oncology: Clinical-stage biotech developing antibody-based therapeutics (including antibody-drug conjugates and immuno-oncology antibodies) for difficult-to-treat cancers. Comparable in stage, therapeutic modality (antibody-based oncology), and multi-indication pipeline strategy.
• CytomX Therapeutics: Clinical-stage biotech developing a Probody antibody platform designed to target the tumor microenvironment with reduced normal-tissue toxicity. Comparable as an antibody-platform oncology biotech applying novel targeting strategies to solid tumors.
• Salarius Pharmaceuticals: Clinical-stage biotech focused on treatments for sarcomas (including osteosarcoma) and other cancers, with both small-molecule and antibody programs. Directly comparable as a competitor in the same pediatric osteosarcoma indication.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innova Therapeutics